PortfoliosLab logo
bioAffinity Technologies Inc. (BIAF)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date

Sep 1, 2022

Highlights

Market Cap

$8.57M

EPS (TTM)

-$0.75

Total Revenue (TTM)

$6.96M

Gross Profit (TTM)

$2.55M

EBITDA (TTM)

-$6.54M

Year Range

$0.24 - $2.99

Target Price

$6.00

Short %

2.93%

Short Ratio

0.01

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
BIAF vs. QQQ
Popular comparisons:

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in bioAffinity Technologies Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%NovemberDecember2025FebruaryMarchApril
-94.34%
40.39%
BIAF (bioAffinity Technologies Inc.)
Benchmark (^GSPC)

Returns By Period

bioAffinity Technologies Inc. (BIAF) returned -48.35% year-to-date (YTD) and -80.82% over the past 12 months.


BIAF

YTD

-48.35%

1M

80.77%

6M

-65.69%

1Y

-80.82%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-5.31%

1M

-0.76%

6M

-4.21%

1Y

10.59%

5Y*

14.55%

10Y*

10.23%

*Annualized

Monthly Returns

The table below presents the monthly returns of BIAF, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-16.49%-34.20%-48.00%80.77%-48.35%
20246.77%47.77%-12.93%21.29%-2.04%-10.00%15.28%-39.76%38.67%-31.25%-15.03%-25.10%-38.12%
202363.12%-34.87%11.18%3.17%-6.15%-0.00%-3.83%-1.70%-32.73%8.40%31.58%-11.42%-8.09%
2022-64.94%-2.06%-5.26%-40.74%-80.72%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BIAF is 35, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BIAF is 3535
Overall Rank
The Sharpe Ratio Rank of BIAF is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of BIAF is 6363
Sortino Ratio Rank
The Omega Ratio Rank of BIAF is 6161
Omega Ratio Rank
The Calmar Ratio Rank of BIAF is 55
Calmar Ratio Rank
The Martin Ratio Rank of BIAF is 99
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for bioAffinity Technologies Inc. (BIAF) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for BIAF, currently valued at -0.24, compared to the broader market-2.00-1.000.001.002.003.00
BIAF: -0.24
^GSPC: 0.47
The chart of Sortino ratio for BIAF, currently valued at 0.92, compared to the broader market-6.00-4.00-2.000.002.004.00
BIAF: 0.92
^GSPC: 0.79
The chart of Omega ratio for BIAF, currently valued at 1.11, compared to the broader market0.501.001.502.00
BIAF: 1.11
^GSPC: 1.12
The chart of Calmar ratio for BIAF, currently valued at -0.83, compared to the broader market0.001.002.003.004.005.00
BIAF: -0.83
^GSPC: 0.49
The chart of Martin ratio for BIAF, currently valued at -1.45, compared to the broader market-10.00-5.000.005.0010.0015.0020.00
BIAF: -1.45
^GSPC: 1.94

The current bioAffinity Technologies Inc. Sharpe ratio is -0.24. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of bioAffinity Technologies Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-0.24
0.47
BIAF (bioAffinity Technologies Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


bioAffinity Technologies Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-94.34%
-9.36%
BIAF (bioAffinity Technologies Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the bioAffinity Technologies Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the bioAffinity Technologies Inc. was 96.87%, occurring on Mar 31, 2025. The portfolio has not yet recovered.

The current bioAffinity Technologies Inc. drawdown is 94.34%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.87%Sep 2, 2022645Mar 31, 2025

Volatility

Volatility Chart

The current bioAffinity Technologies Inc. volatility is 152.67%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%NovemberDecember2025FebruaryMarchApril
152.67%
14.10%
BIAF (bioAffinity Technologies Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of bioAffinity Technologies Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of bioAffinity Technologies Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -12.1%.

-1.20-1.00-0.80-0.60-0.40-0.200.00AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
-0.19
-0.17
Actual
Estimate

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items